Search company, investor...
Clover Biopharmaceuticals company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Date of IPO


Market Cap


About Clover Biopharmaceuticals

Clover Biopharmaceuticals (2197.HK) is a biotechnology company focused on developing novel and transformative biologic therapies, with a focus on oncology and autoimmune diseases.

Clover Biopharmaceuticals Headquarters Location

B-A10 Room No.1, Mansion, Chengdu Hi-tech Zone, Hi-tech Incubation Park Tianhe Incubator, Nan Yan Xian Tian Fu Avenue

Chengdu, Sichuan, 610041,


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Clover Biopharmaceuticals

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Clover Biopharmaceuticals in 2 CB Insights research briefs, most recently on Aug 5, 2021.

Expert Collections containing Clover Biopharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Clover Biopharmaceuticals is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Latest Clover Biopharmaceuticals News

Clover's COVID-19 Vaccine Candidate Receives European Union GMP Certificate

Sep 20, 2022

09/19 09/20/2022 | 04:44am EDT Message : *Required fields SHANGHAI, China, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd . (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, today announced that Clover’s contract development and manufacturing organization (CDMO) has received a European Union Good Manufacturing Practice (EU GMP) certificate for the production of Clover’s lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum). The EU GMP certificate is in connection with Clover’s regulatory submission to the European Medicines Agency (EMA) and follows a successful inspection of the CDMO site by the Ireland Health Products Regulatory Authority. It signifies that the production of SCB-2019 meets the EU’s standards for quality and safety. “Obtaining the EU GMP certificate for SCB-2019 is a major milestone in our efforts to bring our premier COVID-19 vaccine candidate to global markets and a testament to the significant progress our team has made towards commercial readiness,” said Joshua Liang, Chief Executive Officer and Executive Director of Clover. “We would like to thank our CDMO partner for their ongoing collaboration and look forward to getting SCB-2019 across the regulatory finish line.” Clover is working towards completing regulatory submissions to the China National Medical Products Administration (NMPA), the EMA, and the World Health Organization (WHO) for SCB-2019 in the second half of 2022, while concurrently preparing for its commercialization in China and globally upon receiving regulatory approvals. About SCB-2019 (CpG 1018/Alum) Employing the Trimer-Tag™ technology platform, Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein (referred to as S-Trimer™) based on the original strain of the SARS-CoV-2 virus. Clover created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavax’s (Nasdaq: DVAX) CpG 1018 advanced adjuvant and aluminum hydroxide (alum). About Clover Biopharmaceuticals Clover Biopharmaceuticals is a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutics. The Trimer-Tag™ technology platform is a product development platform for the creation of novel vaccines and biologic therapies. Clover leveraged the Trimer-Tag™ technology platform to become a COVID-19 vaccine developer and created SCB-2019 (CpG 1018/Alum) to address the COVID-19 pandemic caused by SARS-CoV-2. For more information, please visit Clover's website:  and follow the company on  LinkedIn and Twitter . Clover Forward-looking Statements This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Participant to the requirements of applicable laws, rules and regulations, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements contained in this document are qualified by reference to this cautionary statement. Clover Biopharmaceuticals:

Clover Biopharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Clover Biopharmaceuticals Rank

  • When was Clover Biopharmaceuticals founded?

    Clover Biopharmaceuticals was founded in 2007.

  • Where is Clover Biopharmaceuticals's headquarters?

    Clover Biopharmaceuticals's headquarters is located at B-A10 Room No.1, Mansion, Chengdu Hi-tech Zone, Hi-tech Incubation Park, Chengdu.

  • What is Clover Biopharmaceuticals's latest funding round?

    Clover Biopharmaceuticals's latest funding round is IPO.

  • How much did Clover Biopharmaceuticals raise?

    Clover Biopharmaceuticals raised a total of $347.77M.

  • Who are the investors of Clover Biopharmaceuticals?

    Investors of Clover Biopharmaceuticals include Hillhouse Capital Management, Delos Capital, OrbiMed Advisors, Temasek, Oceanpine Capital and 7 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.